Tags

Type your tag names separated by a space and hit enter

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Best Pract Res Clin Endocrinol Metab. 2009 Feb; 23(1):103-16.BP

Abstract

Abdominal obesity is associated with numerous metabolic abnormalities, including insulin resistance, impaired glucose tolerance/type-2 diabetes, and atherogenic dyslipidaemia with low high-density lipoprotein (HDL) cholesterol, high triglycerides, and increased small dense low-density lipoprotein (LDL) cholesterol. A proportion of these metabolic disorders may be attributed to increased endocannabinoid activity. The selective cannabinoid 1 (CB1) receptor antagonist rimonabant has been shown to reduce body weight, waist circumference, insulin resistance, triglycerides, dense LDL, C-reactive protein (CRP), and blood pressure, and to increase HDL and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Besides an improvement in glucose tolerance in non-diabetic subjects, a reduction of 0.5-0.7% in haemoglobin A1C (HbA(1c)) levels was consistently observed in various groups of patients with type-2 diabetes. Almost half the metabolic changes could not be explained by weight loss, supporting direct peripheral effects of rimonabant. Ongoing studies should demonstrate whether improved metabolic disorders with CB1 receptor antagonists (rimonabant, taranabant, etc.) would translate into fewer cardiovascular complications among high-risk individuals.

Authors+Show Affiliations

Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman (B35), University of Liège, B 4000 Liège, Belgium. andre.scheen@chu.ulg.ac.beNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19285264

Citation

Scheen, André J., and Nicolas Paquot. "Use of Cannabinoid CB1 Receptor Antagonists for the Treatment of Metabolic Disorders." Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 23, no. 1, 2009, pp. 103-16.
Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab. 2009;23(1):103-16.
Scheen, A. J., & Paquot, N. (2009). Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Practice & Research. Clinical Endocrinology & Metabolism, 23(1), 103-16. https://doi.org/10.1016/j.beem.2008.09.001
Scheen AJ, Paquot N. Use of Cannabinoid CB1 Receptor Antagonists for the Treatment of Metabolic Disorders. Best Pract Res Clin Endocrinol Metab. 2009;23(1):103-16. PubMed PMID: 19285264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. AU - Scheen,André J, AU - Paquot,Nicolas, PY - 2009/3/17/entrez PY - 2009/3/17/pubmed PY - 2009/5/27/medline SP - 103 EP - 16 JF - Best practice & research. Clinical endocrinology & metabolism JO - Best Pract Res Clin Endocrinol Metab VL - 23 IS - 1 N2 - Abdominal obesity is associated with numerous metabolic abnormalities, including insulin resistance, impaired glucose tolerance/type-2 diabetes, and atherogenic dyslipidaemia with low high-density lipoprotein (HDL) cholesterol, high triglycerides, and increased small dense low-density lipoprotein (LDL) cholesterol. A proportion of these metabolic disorders may be attributed to increased endocannabinoid activity. The selective cannabinoid 1 (CB1) receptor antagonist rimonabant has been shown to reduce body weight, waist circumference, insulin resistance, triglycerides, dense LDL, C-reactive protein (CRP), and blood pressure, and to increase HDL and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. Besides an improvement in glucose tolerance in non-diabetic subjects, a reduction of 0.5-0.7% in haemoglobin A1C (HbA(1c)) levels was consistently observed in various groups of patients with type-2 diabetes. Almost half the metabolic changes could not be explained by weight loss, supporting direct peripheral effects of rimonabant. Ongoing studies should demonstrate whether improved metabolic disorders with CB1 receptor antagonists (rimonabant, taranabant, etc.) would translate into fewer cardiovascular complications among high-risk individuals. SN - 1878-1594 UR - https://www.unboundmedicine.com/medline/citation/19285264/Use_of_cannabinoid_CB1_receptor_antagonists_for_the_treatment_of_metabolic_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1521-690X(08)00098-5 DB - PRIME DP - Unbound Medicine ER -